Literature DB >> 34562520

Choline-induced SLC5A7 impairs colorectal cancer growth by stabilizing p53 protein.

Yuan Yin1, Zhiyuan Jiang1, Jiamei Fu2, Yang Li3, Chao Fang1, Xiaonan Yin1, Ye Chen4, Na Chen2, Junshu Li2, Yanhong Ji2, Xiaolan Su2, Meng Qiu4, Wei Huang5, Bo Zhang6, Hongxin Deng7, Lei Dai8.   

Abstract

The members of the solute carrier (SLC) superfamily are vital membrane transporters in human cells. In the present study, we determine the expression and function of SLC5 family members in colorectal cancer (CRC). Expression analysis based on The Cancer Genome Atlas database and potential clinical relation analysis based on the Oncomine database indicate that SLC5A7 is downregulated and is predicted to correlate with the staging, and prognosis response of CRC. Additional results demonstrate that SLC5A7 is downregulated and correlates with good prognosis in patients with CRC. Ectopic expression of SLC5A7 either by overexpression, or uptake of choline efficiently inhibits CRC growth. Examination of the molecular mechanism reveals that SLC5A7 promotes p53 protein expression by directly interacting with and modifying p53 and disrupting the interaction between p53 and MDM2 in wild type p53 CRC cells. Our findings establish the clear correlation between SLC5A7 and tumour growth, providing a novel potential therapeutic target for CRC.
Copyright © 2021. Published by Elsevier B.V.

Entities:  

Keywords:  Colorectal cancer; MDM2; SLC5A7; p53

Mesh:

Substances:

Year:  2021        PMID: 34562520     DOI: 10.1016/j.canlet.2021.09.027

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  1 in total

1.  Targeted demethylation of the SLC5A7 promotor inhibits colorectal cancer progression.

Authors:  Yang Li; Baike Liu; Xiaonan Yin; Zhiyuan Jiang; Chao Fang; Na Chen; Bo Zhang; Lei Dai; Yuan Yin
Journal:  Clin Epigenetics       Date:  2022-07-20       Impact factor: 7.259

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.